Research programme: therapeutics - Algernon Pharmaceuticals
Latest Information Update: 28 Dec 2023
At a glance
- Originator Nash Pharmaceuticals
- Developer Algernon Pharmaceuticals
- Class Anti-inflammatories; Antifibrotics; Hepatoprotectants; Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Idiopathic pulmonary fibrosis; Renal failure
- No development reported Inflammatory bowel diseases; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in Canada
- 28 Dec 2023 No recent reports of development identified for preclinical development in Renal-failure in Canada
- 27 Dec 2023 Preclinical development is ongoing in Renal failure and Idiopathic pulmonary fibrosis in Canada